Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Study of ALXN1007 in Subjects With Newly Diagnosed Acute Graft-Versus-Host Disease Involving the Lower Gastrointestinal Tract

NCT02245412 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02245412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02245412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Study of ALXN1007 in Subjects With Newly Diagnosed Acute Graft-Versus-Host Disease Involving the Lower Gastrointestinal Tract
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 14, 2014
Completion date
February 27, 2017
Enrollment
25 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft-versus-host disease, gigvhd